2024 Partners
2024 파트너사
2024 合作伙伴
2024 パートナー
Lead Partner
Abzena
Abzena is a life science group with headquarters in the UK, and chemistry and manufacturing sites in the US. Abzena’s complimentary services and technologies in chemistry, biology and manufacturing, are applied to the selection, development and manufacture of better biopharmaceuticals. Abzena works with most of the top 20 biopharmaceutical companies and academic groups all over the world and is focused on enabling the development of better treatments for patients. Abzena’s technologies have enabled many of its customers to progress products through to clinical development. Abzena was created through the incorporation of Antitope, PacificGMP, PolyTherics and The Chemistry Research Solution (TCRS); all of whom now trade as Abzena.
Partners
Ajinomoto Biopharma Services
Ajinomoto Bio-Pharma Services offers comprehensive capabilities for small molecule APIs and biologics production, from process development and cGMP manufacturing to aseptic fill finish,
including cytotoxics. As a global CDMO, they provide the adaptive solutions, responsive service, trusted partnership and peace of mind you’ve come to rely on.
BSP Pharmaceuticals
OminAb
Samsung Biologics
Samsung Biologics is a fully integrated CDMO partner of choice, providing highly tailored solutions to clients while meeting the evolving needs of the global healthcare industry. With proven regulatory approvals, we provide seamless offerings from cell-line development to final fill/finish at every stage for biopharmaceutical products. Our plants are cGMP compliant with a wide range of bioreactor scales to serve varying client needs and meet growing market demand. We hold a total capacity of 604KL at Bio Campus I, the world’s largest biomanufacturing site, and have announced plans to construct a fifth plant, which will be operational in 2025.
Thousand Oaks Biologics
Shanghai ADC site include bioreactors, purification equipment, and fill-finish lines. TOBio’s comprehensive quality management system ensures compliance with ICH, US FDA, EU EMA, and China NMPA standards. With a proven track record of successful project delivery, including over 100 clinical – stage projects and 3 pre-Approval inspections, TOBio is a trusted global
CDMO for biopharmaceutical companies.
WuXi XDC
WuXi XDC is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products.
Exhibitors
Asymbio
AsymBio is the emerging business unit of Asymchem Group striving to become a
technology-driven, fully-empowered one-stop CDMO services platform for biologic (mAb, ADC, plamsid&mRNA), offering customized services with outstanding quality and efficient performance. We have built an integrated and comprehensive CDMO service platform for ADC drugs (payload-linker, mAb, conjugation), which including but not limited to development,
manufacturing, quality control and regulatory affairs. Our one-stop ADC CDMO service platform is able to efficiently empower ADCs.
Cytiva
Cytiva, now with the life sciences business from Pall Corporation, is a global biotechnology leader dedicated to helping customers discover and commercialize the next generation of therapeutics. We bring dedicated technical expertise and a broad portfolio of tools, technologies, and services that enable the development, manufacture, and delivery of transformative medicines to patients.
Aton Bio
Aton Biotech is a fast-growing CDMO company which is committed to enabling new biological drugs for clients with an integrated bio-pharmaceutical platform. Our service ranges from cell line development to clinical and end-to-end CDMO commercial manufacturing services, including development of mammalian expressed monoclonal antibodies, fusion proteins, bispecific antibodies, ADC, etc.
Axplora
Axplora, created from the merger of Farmabios, Novasep and PharmaZell, is a leading API manufacturing partner to the world’s leading pharmaceutical and biotechnology companies, delivering top quality active ingredients on time and at scale, to the highest industry standards. Axplora is dedicated to helping pharmaceutical companies make critical medicines better, faster, safely, reliably, and sustainably benefitting patients worldwide. The group provides unique services for the development, fast-track, clinical supply and commercial cGMP manufacture of ADCs including the payload-linker and the bioconjugation, leveraging its in-house purification expertise, HPAPI culture & state-of-the art cGMP conjugation facilities. We offer a full and flexible range of ADC manufacturing services with hand-run experience on different conjugation platforms.
Levena Biopharma
LEVENA is headquartered in Suzhou, China and has R&D centers and GMP manufacturing sites in Nanjing and San Diego, with a total of about 20,000m2 of R&D and GMP manufacturing sites, covering antibody, drug-linker, conjugation and lyophilization. Aimed to truly realize the one-stop service of ADC.
As a leading enterprise of Antibody-drug conjugate (ADC), LEVENA has been committed to the development and industrialization of ADC. The company has the world's leading new generation of site-specific conjugation technology and a number of conjugate-related patents. At present, the company has a mature and professional core technology platform, covering the research and development and production of highly efficacious toxins (including Duostatins (Tubulin inhibitors), Duomycins (DNA alkylating agents), and Camptothecins), and various site-specific conjugation methods (K-Lock, C-Lock,C-Lock DXD and High DAR low toxicity platform). Based on this, it has carried out extensive cooperation with domestic and foreign pharmaceutical companies in the research and development of new drugs.
LEVENA's patent platform has achieved all-round coverage from low toxicity high DAR to high toxicity low DAR. Can meet the diverse needs of different requirements. At the same time, based on the flexible application of platform technology, LEVENA can realize customized drug-linker recommendation for specific projects and needs, help quickly and efficiently screen out the best pre-clinical candidate ADC, and accelerate the whole project cycle.
PROVEO
Formed in 2015, PROVEO is now a Division of Cerbios- Pharma SA focused on complete
supply chain solution for Antibody Drug Conjugates (ADCs). Thanks to the partnership with AGC Biologics and Oncotec, PROVEO offer best-in-class solutions for the integrated development and cGMP manufacturing of recombinant proteins (incl mAbs), cytotoxic drug-linker payload, conjugation, aseptic fill and lyophilization. Strengths of the three PROVEO partners secure a seamless and low risk ADC supply chain for clinical and commercial projects.
Henlius
Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Up to date, 5 products have been launched in China, 2 have been approved for marketing in overseas markets, 19 indications are approved worldwide, and 7 marketing applications have been accepted for review in China, the U.S., and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centers and Shanghai-based manufacturing facilities in line with global Good Manufacturing Practice (GMP), including Xuhui Facility and Songjiang First Plant, both certificated by China and the EU GMP.
Henlius has pro-actively built a diversified and high-quality product pipeline covering over 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as backbone. Apart from the launched products HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab for injection, trade name in Europe: Zercepac®), the first China-developed mAb biosimilar approved both in China and Europe, HANDAYUAN (adalimumab) and HANBEITAI (bevacizumab), the innovative product HANSIZHUANG has been approved by the NMPA for the treatment of MSI-H solid tumours, squamous non-small cell lung cancer (sqNSCLC) and extensive-stage small cell lung cancer (ES-SCLC), and esophageal squamous cell carcinoma (ESCC), making it the world's first anti-PD-1 mAb for the first-line treatment of SCLC. What's more, Henlius has conducted over 30 clinical studies for 16 products, expanding its presence in major markets as well as emerging markets.
GenScript Biotech Korea
Sterling Pharma Solutions
Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO), with 50 years’ experience in small molecule API development and manufacturing services. In April 2021 Sterling acquired ADC Bio, a UK based biotechnology company specialising in antibody drug conjugates and bioconjugation. Together, as Sterling Pharma Solutions, the teams have developed an integrated service offering for existing and potential customers, which combines ADC Bio’s expertise with Sterling’s high potency small molecule expertise.
Sterling has four facilities employing more than 800 people: its HQ in Dudley, Northumberland, UK; a dedicated bioconjugation and ADCs facility in Deeside, North Wales, UK; and two sites in the US, in Cary, North Carolina and Germantown, Wisconsin.
ILC Dover
ILC Dover is a world-leader in the innovative design and production of solutions for biotherapeutic, pharmaceutical, medical device markets as well as a leading supplier for the (aero)space industries. Our customers will attest to our relentless dedication to high value products, advanced technology, and responsive service, as our visionary solutions have improved efficiency while safeguarding people, product, and infrastructure in hazardous conditions through flexible protective solutions since 1947. For more information on ILC Dover, please visit: